Line 166: |
Line 166: |
| !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> BRAF and MAP2K1; Activating mutations | + | |<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations |
| |<span class="blue-text">EXAMPLE:</span> MAPK signaling | | |<span class="blue-text">EXAMPLE:</span> MAPK signaling |
| |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation | | |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> CDKN2A; Inactivating mutations | + | |<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations |
| |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation | | |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation |
| |<span class="blue-text">EXAMPLE:</span> Unregulated cell division | | |<span class="blue-text">EXAMPLE:</span> Unregulated cell division |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> KMT2C and ARID1A; Inactivating mutations | + | |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations |
| |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling | | |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling |
| |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program | | |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program |